REFERENCES

- 1. Glass WG et al. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. *J Exp Med.* 202 (8):1087–98 (2005).
- 2. Yedavalli VS et al. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. *Cell.* 119(3):381–92 (2004).
- 3. Kovacs JA et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. *J Clin Invest*. 115:2139–2148 (2005).
- 4. Burke JP. Infection control—a problem for patient safety. *N Engl J Med.* 348(7):651–656 (2003).
- 5. CDC Division of Bacterial and Mycotic Diseases [Internet]. Campaign to Prevent Antimicrobial Resistance in Healthcare Settings, October 2005. Available from: www.cdc.gov/drugresistance.
- 6. NIAID [Internet]. The Problem of Antibiotic Resistance, April 2004. Available from: www.niaid.nih.gov/factsheets/antimicro.htm.
- 7. Blot SI et al. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant *Staphylococcus aureus*. *Arch Intern Med.* 162(19):2229–35 (2002).
- 8. Cosgrove SE et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* bacteremia: a meta-analysis. *Clin Infect Dis.* 36(1):53–9 (2003).
- 9. Carmeli Y et al. Health and economic outcomes of vancomycin-resistant enterococci. *Arch Intern Med.* 162(19):2223–8 (2002).

- 10. CDC Division of Bacterial and Mycotic Diseases [Internet]. Campaign to Prevent Antimicrobial Resistance in Healthcare Settings, October 2005. Available from: http://www.cdc.gov/drugresistance/healthcare/problem.htm; CDC Division of Bacterial and Mycotic Diseases [Internet]. Drug-Resistant Streptococcus pneumoniae Disease, October 2005. Available from: http://www.cdc.gov/ncidod/dbmd/diseaseinfo/drugresisstreppneum_t.htm.
- 11. CDC. Prevention of Perinatal Group B Streptococcal Disease. *MMWR* 2002; 51 (No. RR-11):1–24.
- 12. CDC [Internet]. Frequently Asked Questions about Malaria, October 2005. Available from: http://www.cdc.gov/malaria/faq.htm.
- 13. WHO [Internet]. Executive Summary, Third Global Report: WHO/IUATLD (International Union Against Tuberculosis and Lung Disease) Global Project on Anti-Tuberculosis Drug Resistance Surveillance, 2004. Available from: http://whqlibdoc.who.int/publications/2004/9241562854.pdf.
- Taylor DN. The growing problem of antimicrobial resistance among enteric pathogens. Clin Updates Infect Dis. 6:1–3 (2003).
- 15. Parry CM. Antimicrobial drug resistance in *Salmonella enterica. Curr Opin Infect Dis.*16:467–472 (2003).
- 16. Tjaniadi P et al. Antimicrobial resistance of bacterial pathogens associated with diarrheal patients in Indonesia. *Am J Trop Med Hyg.* 68:666–670 (2003).
- 17. Kocianova S et al. Key role of poly-gamma-DL-glutamic acid in immune evasion and virulence of *Staphylococcus epidermidis*. *J Clin Invest*. 115(3):688–94 (2005).
- 18. Voyich, JM et al. Insights into mechanisms used by *Staphylococcus aureus* to avoid destruction by human neutrophils. *J Immunol.* 175(6):3907–3919 (2005).

- 19. NIAID [Internet]. Allergy Statistics. Available from: http://www.niaid.nih.gov/factsheets/allergystat.htm; American Academy of Allergy, Asthma and Immunology (AAAAI). [Internet] The Allergy Report. Available from: http://www.aaaai.org/ar/default.stm.
- 20. Matricardi PM et al. Hay fever and asthma in relation to markers of infection in the United States. *J Allergy Clin Immunol.* 110:381–387 (2002).
- 21. Sampson H. Peanut allergy. *N Engl J Med.* 346:1294–1299 (2002).
- 22. Morgan WJ et al. Results of a home-based environmental intervention among urban children with asthma. *N Engl J Med.* 351:1068–80 (2004).
- 23. Katten M et al. Cost-effectiveness of a home-based environmental intervention for inner-city children with asthma. *J Allergy Clin Immunol*. 116(5):1058–63 (2005).
- 24. Moayeri M et al. Endocrine perturbation increases susceptibility of mice to anthrax lethal toxin. *Infect Immun*. 73:4238–4244 (2005).
- 25. Sebbane F et al. Kinetics of disease progression and host response in a rat model of bubonic plague. *Am J Pathol.* 166:1427–1439 (2005).
- 26. Kobayashi SD et al. Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. *Proc Nat'l Acad Sci USA*. 100:10948–10953 (2003).
- 27. Earl PL et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. *Nature*. 428:182–185 (2004).
- 28. Chesebro B et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. *Science*. 308:1435–1439 (2005).
- 29. Ibid.

- 30. Bisht H et al. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an Nterminal segment of the spike glycoprotein. Virology. 334(2):160–165 (2005); Greenough TC et al. Development and characterization of a severe acute respiratory syndromeassociated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis. 191(4):507–514 (2005), Epub 2005 Jan 14; Roberts A et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol. 79(1):503-511 (2005).
- 31. CDC. Final 2004 Reports of Notifiable Diseases. *MMWR* 54(31):770 (2005).
- 32. Silveira JR et al. The most infectious prion protein particles. *Nature*. 437(7056):257–261 (2005).
- 33. Chesebro B et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. *Science*. 308(5727):1435–1439 (2005).
- 34. Kocisko DA et al. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. *Antimicrob Agents Chemother*. 50(3):1034–1044 (2006).
- 35. WHO [Internet]. Hepatitis C Fact Sheet No. 164, revised October 2000. Available from: www.who.int/mediacentre/factsheets/fs164/en; Centers for Disease Control and Prevention (CDC) [Internet]; Hepatitis Surveillance: Report Number 60, p. 39, issued September 2005. Available from: www.cdc. gov/ncidod/diseases/hepatitis/resource/PDFs/hep_surveillance_60.pdf.
- 36. CDC [Internet]. Viral Hepatitis C fact sheet, reviewed January 2005. Available from: www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm.
- 37. Ibid.

- 38. NIH [Internet]. National Institutes of Health Consensus Development Conference Statement, Management of Hepatitis C: 2002. June 10–12, 2002. Available from: consensus. nih.gov/2002/2002HepatitisC2002116html. htm.
- 39. Bartosch B et al. *In vitro* assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. *Proc Nat'l Acad Sci USA*. 100:14199–14204 (2003).
- 40. Meunier J-C et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudoparticles and enhancement of infectivity by apolipoprotein C1. *Proc Natl Acad Sci USA*. 102:4560–4565 (2005).
- 41. Schofield DJ et al. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. *Hepatology*. 42(5):1055–1062 (2005).
- 42. Special Programme for Research and Training in Tropical Diseases (TDR) [Internet]. Malaria: Disease Information. Available from: www. who.int/tdr/diseases/malaria/diseaseinfo.htm.
- 43. WHO and UNICEF [Internet]. 2005 World Malaria Report. Available from: rbm.who.int/wmr2005/pdf/adv_e.pdf.
- 44. Morgan, WJ et al. Results of a home-based environmental intervention among urban children with asthma. *N Engl J Med*. 351(11):1068–1080 (2004).
- 45. CDC [Internet]. Viral Hepatitis C fact sheet, reviewed January 2005. Available from: www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm.
- 46. NCCAM [Internet]. Hepatitis C and complementary and alternative medicine: 2003 update. Available from: nccam.nih.gov/health/hepatitisc/index.htm; NIH [Internet]. NIH consensus conference statement on management of hepatitis C: 2002. Available from: consensus. nih.gov/2002/2002HepatitisC2002116html. htm.

- 47. CDC [Internet]. Basic statistics (from the CDC HIV/AIDS Surveillance Report: HIV Infection and AIDS in the United States, 2004.)

 Available from: www.cdc.gov/hiv/topics/
 surveillance/basic.htm#aidscases.
- 48. UNAIDS/WHO [Internet]. AIDS epidemic update: December 2005. Available from: www. unaids.org/epi/2005/index.asp; UNAIDS [Internet]. Women. Available from: www. unaids.org/en/GetStarted/Women.asp.
- 49. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, Cases of HIV Infection and AIDS in the United States, 2004. Vol. 16. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005:1–46.
- 50. NIAID [Internet]. HIV infection in infants and children, July 2004. Available from: www.niaid.nih.gov/factsheets/hivchildren.htm.
- 51. NIAID [Internet]. Strategic plan for addressing health disparities: fiscal years 2002–2006.

 Available from: www.niaid.nih.gov/healthdisparities/NIAID_HD_Plan_Final.pdf.
- 52. CDC [Internet]. STD surveillance 2004. Available from: www.cdc.gov/std/stats/trends2004.htm.
- 53. CDC [Internet]. STD surveillance 2004, National Profile, Chlamydia. Available from: www.cdc.gov/std/stats/chlamydia.htm.
- 54. CDC [Internet]. National overview of sexually transmitted diseases, 2004. Available from: www.cdc.gov/std/stats/natoverview.htm.
- 55. CDC [Internet]. Cases of HIV infection and AIDS in the United States (HIV/AIDS surveillance report, 2004, Vol. 16). Available from: www.cdc.gov/hiv/topics/surveillance/resources/reports/2004report/default.htm.
- 56. CDC [Internet]. STD Prevention—Syphilis Fact Sheet, May 2004. Available from: www.cdc.gov/std/Syphilis/STDfact-Syphilis.htm.

- 57. CDC [Internet]. National overview of sexually transmitted diseases, 2004. Available from: www.cdc.gov/std/stats/natoverview.htm.
- 58. Sorvillo F et al. Trichomonas vaginalis, HIV, and African-Americans. *Emerg Infect Dis.* 7(6):927–932 (2001).
- 59. Kerman RH et al. Influence of race on crossmatch outcome and recipient eligibility for transplantation. *Transplantation*. 53:64–67 (1992); Norman DJ et al. Cadaveric kidney allocation in the United States: a critical analysis of the point system. *Transplant Proc.* 27:800 (1995).
- 60. Beatty PG et al. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. *Transplantation*. 60(8):778–783 (1995).
- 61. WHO [Internet]. Tuberculosis fact sheet No. 104, March 2004. Available from: www.who. int/mediacentre/factsheets/fs104/en; Global tuberculosis control—surveillance, planning, financing, 2004. Available from: www.who. int/tb/publications/global_report/en.
- 62. Pratt R et al. Trends in tuberculosis—United States, 2005. MMWR Weekly. 55(11): 305–308. (March 24, 2006). Available from: www.cdc. gov/mmwr/preview/mmwrhtml/mm5511a3. htm.
- 63. American Social Health Association [Internet]. Learn About STIs/STDs, October 2005. Available from: www.ashastd.org/learn/learn_statistics.cfm.
- 64. CDC [Internet]. STD Surveillance 2004,
 October 2005. Available from: www.cdc.gov/
 std/stats/trends2004.htm; CDC [Internet].
 CDC National Prevention Information
 Network, October 2005. Available from: http://
 www.cdcnpin.org/scripts/std/std.asp.

- 65. Highleyman L. STDs Increase Risk for HIV [Internet]. San Francisco, CA: Bulletin of Experimental Treatment for AIDS, Autumn 2000. Available from: www.thebody.com/sfaf/autumn00/std.html#synergy.
- 66. The Organ Procurement and Transplantation Network [Internet]. Data. March 31, 2006. Available from: www.optn.org/data.
- 67. Ibid.
- 68. Ibid.
- 69. WHO [Internet]. Media Centre: Tuberculosis, April 2005. Available from: www.who.int/mediacentre/factsheets/fs104/en.
- NIAID [Internet]. Tuberculosis Antimicrobial Acquisition and Coordinating Facility: Global discovery program for novel anti-tuberculosis drugs, 2004. Available from: www.taacf.org.
- 71. The PLoS Medicine Editors. A strategy for developing an HIV vaccine. 2(1):0001 (January 2005). Available from: medicine.plosjournals. org/perlserv/?request=get-document&doi=10% 2E1371%2Fjournal%2Epmed%2E0020035.
- 72. Burbacher TM et al. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. *Environ Health Perspec.* 113(8):1015–21. (August 2005) Available from: http://www.ehp.niehs.nih.gov/docs/2005/7712/abstract.html.
- 73. Karron RA et al. Identification of a recombinant live-attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. *J Infect Dis.* 191(7):1093–1104 (2005).